Name: Capsaicin and Spicy Food: What It Actually Does
Creator: Realised
Published: 2026-07-01

Summary

Spicy food does not cause ulcers and is harmless to possibly mildly beneficial for most people, it is a genuine and individually identifiable symptom trigger for a minority with reflux, irritable bowel syndrome or acute anal lesions, and it is meaningfully dangerous only in the form of concentrated extract challenge products.

Why Moderate

This entry is assigned Moderate overall.

Why not Strong. No randomised controlled trial demonstrates a clinically meaningful benefit from dietary capsaicin against any endpoint that matters. The strongest positive evidence is observational, cannot adjust for total energy intake, is measured by a single self-reported frequency item, and is conceded by its own authors to be vulnerable to residual confounding and reverse causation. The metabolic trials are properly randomised but address acute surrogate endpoints — single-meal intake and chamber-measured expenditure — and do not extend to any maintained weight outcome. A body of evidence whose best design addresses the least important outcome cannot carry a Strong rating.

Why not Emerging. The evidence base is not preliminary. The mortality cohort is very large, prospectively collected, and internally consistent across cause-specific outcomes. The metabolic meta-analyses pool real randomised trials. The safety picture includes a randomised placebo-controlled trial in a specific acute condition. And the central negative claim — that spicy food does not cause ulcers — is not merely moderate but settled at the highest strength this corpus recognises. An entry containing a Foundational refutation and multiple pooled randomised datasets is above Emerging.

Per-sub-area split, because the overall tier flattens real differences:
• TRPV1 pharmacology and the sensation-versus-damage distinction: Foundational. Basic receptor science, not in dispute.
• Ulcer causation by H. pylori and NSAIDs, and the exclusion of capsaicin: Foundational. Nobel-recognised, decades old, universally accepted in gastroenterology.
• Directed deterrence and the bird/mammal asymmetry: Strong as a fact about chilli ecology, and explicitly not applicable to human physiology. The receptor-level explanation for the asymmetry is reported but was not verified to primary source here.
• Mortality association in large cohorts: Moderate. Large and consistent, structurally unable to establish causation, and plateauing rather than grading with intake.
• United States cohort replication specifically: Emerging. Single baseline food-frequency item carried across nineteen years, an adjusted hazard ratio whose upper bound sits at 0.97, and severe baseline differences between groups.
• Thermogenic and appetite effects: Moderate. Pooled randomised evidence, real effects, acute endpoints, high heterogeneity, no long-term outcome data.
• Gastroprotection: Emerging and rodent-flagged. Coherent mechanism, thin human data, no clinical endpoints.
• Reflux symptom triggering as an individual phenomenon, with blanket restriction unsupported: Moderate, resting on a systematic evidence review.
• Irritable bowel syndrome triggering: Emerging, and stated generically because no specific trial was verified to primary source for this entry.
• Acute anal fissure and post-haemorrhoidectomy worsening: Emerging despite good design on the fissure trial, because both trials are small, single-centre and from the same single investigator, and the haemorrhoidectomy trial was not placebo-controlled.
• Extreme-extract challenge harm: Emerging. A single verified fatal case with a documented confounding cardiac anomaly, plus an unverified wider case literature.

Practical takeaway

If you have a healthy gut and you like spicy food: eat it. There is no reason to restrict it and no plausible mechanism by which ordinary culinary quantities damage you. The mortality epidemiology is not strong enough to be a reason to eat more, but it is more than strong enough to remove any residual worry about eating what you enjoy.

If you have a healthy gut and you do not like spicy food: there is nothing here worth starting for. The metabolic effects are too small to matter and the longevity association is not established as causal. Anyone telling you to force down chilli for your health is selling something or repeating someone who is.

If you are using chilli or capsaicin extracts for weight management: stop expecting it to work as a lever. Fifty calories a day of extra expenditure and seventy-four calories less at a single meal are real measurements, and neither has been shown to produce weight change over any meaningful period. The two figures come from different reviews and cannot be added together. Habituation likely erodes the effect in exactly the people who use chilli most.

If you have reflux: do not adopt a blanket spicy-food ban on general principle, because the evidence does not support it and unnecessary restriction has its own cost. Do pay attention to whether chilli reliably precedes your own symptoms, and if it does, avoid it for that reason. The interventions with actual evidence behind them in reflux are weight loss and elevating the head of the bed. The full picture belongs to the reflux entry.

If you have irritable bowel syndrome, particularly the diarrhoea-predominant form: treat chilli as a plausible individual trigger and test it deliberately rather than either banning it permanently or ignoring the possibility. Remove it for a defined period, reintroduce it, and observe. The evidence supports suspicion, not certainty.

If you have an acute anal fissure or have recently had haemorrhoid surgery: avoid chilli during the acute period. This is one of the very few "avoid spicy food" instructions with a randomised placebo-controlled trial behind it — one trial, from one investigator, so hold it as a sensible precaution rather than as settled fact. It is a temporary measure tied to an acute lesion, not a permanent dietary rule.

If you have an ulcer or persistent upper abdominal pain: the relevant action is diagnostic, not dietary. Get tested for H. pylori and review any regular NSAID or aspirin use with whoever prescribes it. Changing what you eat while leaving an untreated infection in place is the specific failure this entry exists to prevent.

Never do the challenge products. Concentrated pepper extracts at heat levels no cuisine has ever produced are not food, and the harm profile is dominated by cardiovascular events in people who did not know they were vulnerable. There is no version of this that is a health decision.

Evidence detail

Why This Entry Exists

Capsaicin is one of the few dietary topics where the popular wisdom is wrong in both directions at once, and the two errors have different ages. The older error is medical: for most of the twentieth century, people with stomach ulcers were told to eat bland food and avoid chilli. That instruction was issued in good faith by clinicians who did not yet know that peptic ulcers are an infectious and drug-induced disease. The discovery that changed it is now four decades old and carries a Nobel Prize, and yet the advice outlived the theory it rested on. Most people who believe spicy food burns holes in the stomach are repeating a pre-1983 medical consensus without knowing that is what they are doing.

The newer error runs the other way. Since roughly 2015, a very large Chinese cohort study and a smaller American one have been used to sell chilli as a longevity food, and a pair of meta-analyses on energy expenditure and appetite have been used to sell capsaicin extracts as fat burners. In both cases the coverage went further than the data — but, and this matters, not always further than the authors. The mortality cohort is the honest one: its own paper lists residual confounding, absent energy adjustment and reverse causation as limitations, and none of those caveats survive the trip to a supplement label. The thermogenesis reviews are a different story, and the entry has to be straight about it. The widely quoted line that capsaicinoids are "not a magic bullet for weight loss" is a concessive clause inside a sentence that goes on to say they "could play a beneficial role, as part of a weight management program," and the same group's later meta-analysis concludes that there "may be potential for capsaicinoids to be used as long-term, natural weight-loss aids." The projection of clinically significant weight loss over one to two years, which is the number that ends up on labels, is the review authors' own arithmetic, not something the marketing invented. So the restraint on this topic does not come from the primary literature. It has to come from the reader.

What sits between those two errors is unglamorous and correct: for a person with an intact gut, chilli is a food, not a drug and not a hazard. It produces a real sensation through a real receptor without producing real tissue damage. It is worth eating if you like it and not worth starting if you do not. And for a specific minority of people with specific conditions, it reliably makes their symptoms worse, which is a fact about them rather than a fact about chilli.

What bad advice this protects against, in all directions:
• "Spicy food burns your stomach and causes ulcers." Wrong, and cleanly so. Peptic ulcers are overwhelmingly caused by Helicobacter pylori infection and by non-steroidal anti-inflammatory drug use, with a small residue from Zollinger-Ellison syndrome, critical illness and idiopathic causes. Capsaicin does not appear on the causal list in any modern review. The myth survives because it confuses sensation with pathology: capsaicin activates heat-sensing nerve endings and produces a genuine burning feeling, and a burning feeling is a nerve signal, not an erosion. It is self-reinforcing, too, because a person who already has gastritis or an ulcer will genuinely feel worse after chilli, and will read that as confirmation when it is simply an existing lesion being reported by intact pain fibres.
• "Chilli boosts your metabolism and helps you lose weight." Over-read. The thermogenic effect is real and has been measured properly, and it is roughly fifty extra calories a day, which is about one biscuit and comfortably inside the noise of ordinary day-to-day intake variation. The appetite effect is also real and also small, around seventy-four fewer calories eaten in the single meal following a capsaicin pre-load, measured acutely with high heterogeneity between trials and no long-term weight data at all. The frequently quoted projection of clinically significant weight loss over one to two years is an arithmetic extrapolation from the daily figure, not something any trial observed — and it is the review authors' own extrapolation, which is why quoting it back at them does not work as a correction. Habituation to capsaicin is well documented in regular consumers, which is precisely the population being told to eat more of it.
• "Chilli extends your life, half a million people were studied." The study is real, the numbers are real, and the causal reading is not licensed. Large observational cohorts show people who eat spicy food most days have a lower adjusted hazard of death than people who almost never do. They also could not adjust for total energy intake, measured exposure as a self-reported frequency with no dose and no capsaicin quantity, and were unable to fully exclude the possibility that people who become ill stop eating spicy food. And the adjusted risk stops moving almost as soon as you are eating spicy food at all: the hazard ratio is 0.90 at one to two days a week and then 0.86 at both three to five days and six to seven days. Above roughly two days a week, more is not better. That is the shape of a marker, not the shape of a dose-response.
• "If you have reflux, cut out spicy food." Not supported as a blanket rule. A systematic evidence review of roughly a hundred studies of lifestyle modification in reflux disease found that dietary interventions, including avoiding spicy food, did not improve objective measures or symptoms. Only weight loss and elevating the head of the bed survived. Laboratory work indicates chilli has little to no effect on lower oesophageal sphincter pressure, so it is not producing more reflux; it is activating nerve endings in an already sensitised mucosa. Some individuals flare reliably and should personally avoid it. That is an individual observation, not a population prescription.
• "Spicy food is completely harmless, the ulcer thing was debunked." Over-corrected. Two small randomised trials from a single investigator, one of them genuinely placebo-controlled with the chilli encapsulated, show chilli worsens pain in acute anal fissure and worsens symptoms after haemorrhoid surgery. That is still a higher standard than most food-symptom claims ever meet. Small studies in irritable bowel syndrome point the same way. And a fourteen-year-old boy died in 2023 after an extreme capsaicin extract chip challenge. The ulcer myth being dead does not make capsaicin inert.
• "Chilli protects your stomach lining." Running ahead of the evidence. There is a coherent proposed mechanism and a body of supportive work, but it is predominantly rodent, and the human material is a small number of short mechanistic studies using acute chemical challenge rather than clinical ulcer outcomes. This is the single most likely overclaim in the topic, because it converts a null result into a purchase reason. A person with an untreated H. pylori ulcer who reads that chilli is gastroprotective and delays eradication therapy has been actively harmed.

What this entry OWNS: whether spicy food is harmful; the ulcer myth and its refutation; what capsaicin actually does in the human body; the honest size of the metabolic effects; the strength and the weakness of the mortality epidemiology; and the boundary between ordinary dietary chilli and concentrated extract stunt products.

What this entry DEFERS: the management of gastro-oesophageal reflux disease, including the full diagnostic picture and the interventions that do work, to gerd_diagnostic_lifestyle; the assessment and treatment of haemorrhoids and related anal conditions to hemorrhoids_evidence_and_management; the general theory of why plants make defensive chemicals at all, and what that framing does and does not license, to plant_defence_compounds_and_xenohormesis; and the question of whether mild stressors produce adaptive benefit as a general principle to hormesis_and_adaptive_stress.

Evidence

Read the tiers, not the thesis. The unusual feature of this topic is that the strongest-sounding evidence is the weakest in design, and the best-designed evidence addresses the least important questions. Half a million people in an observational cohort tell you less about causation than forty people in a crossover trial tell you about a symptom, and the crossover trials here are all about narrow acute conditions.

Sub-area A: What capsaicin is and why chillies make it

1. Capsaicin is an agonist at the TRPV1 receptor, the same receptor that reports noxious heat and low pH, which is why chilli is experienced as burning rather than as a taste. [Foundational] This is settled receptor pharmacology and is the mechanistic basis for everything else in the entry.

2. Capsaicin deters mammals but not birds, and this asymmetry appears to serve seed dispersal. [Strong] Field work on wild chillies showed capsaicin selectively deterred mammalian seed predators such as packrats and cactus mice while an avian consumer, the curve-billed thrasher, ate the fruit freely, and seeds passing through the bird germinated well. Species flag, and it is load-bearing: this is a bird, rodent and plant-ecology finding. It says nothing whatsoever about human physiology and must never be presented as explaining a human health effect. It is an excellent origin story and a bad mechanism claim. Note also that the ecological work is field observation on one Capsicum system in one region, so "chillies evolved this on purpose" is an inference about selection pressure rather than a demonstrated evolutionary pathway. Tewksbury and Nabhan, Nature 2001;412:403–404. The molecular leg — that avian TRPV1 responds normally to heat and low pH but not to capsaicin, and that the species difference localises to a single amino acid position in the receptor — is real as a body of work but is not cited to a verified primary source in this entry, because the papers usually invoked for it were not confirmed in this verification pass. Treat the molecular claim as reported-but-unverified here and do not attach figures to it. Cui bono: nobody sells anything directly off this, but it is charismatic and gets repeated by food writers and chilli brands because "the plant made this deliberately, and never for you" launders into an implied safety claim for humans. It buys narrative credibility for the metabolic claims downstream. In the opposite direction there is essentially no interest in suppressing it; the only commercial use is capsaicin-treated birdseed sold as squirrel-proof, which is a legitimate application of the same finding.

Sub-area B: The ulcer question

3. Peptic ulcers are caused by Helicobacter pylori infection and by NSAID use, not by spicy food. [Foundational] Marshall and Warren identified the organism in the stomachs of patients with gastritis and peptic ulceration in 1984 and received the 2005 Nobel Prize in Physiology or Medicine for that discovery and its role in peptic ulcer disease. The remaining cases are dominated by aspirin and NSAID use, with a small residue from Zollinger-Ellison syndrome, critical illness and idiopathic causes. Capsaicin is absent from the causal list. Marshall and Warren, Lancet 1984;1(8390):1311–1315. Cui bono, and this one is stark. Benefiting from the myth persisting: antacid and bland-diet products, and historically the entire pre-1983 ulcer-management industry, which sold indefinite acid suppression and dietary restriction for a condition that turned out to be curable with a short antibiotic course. Marshall's own account is that the discovery met resistance partly because it threatened a large chronic-treatment market. Also benefiting, less commercially: any clinician or family member who prefers a lifestyle-blame explanation to an infectious one. Benefiting from over-correcting: chilli sauce brands and "spicy is good for you" content, which slide from "does not cause ulcers" to "is good for your stomach", a different and far weaker claim handled immediately below.

4. Capsaicin may be mildly gastroprotective, inhibiting acid secretion and stimulating mucosal blood flow. [Emerging] The mechanism is coherent: capsaicin-sensitive afferent neurons release calcitonin gene-related peptide and other neuropeptides that increase gastric mucosal blood flow, and capsaicin has been reported to inhibit acid secretion and stimulate alkali and mucus secretion. Species flag: the bulk of this literature is rodent. The human material is a small number of short mechanistic studies, several from the same research groups, typically using acute aspirin or ethanol challenge with endoscopic or mucosal-damage endpoints in small samples. There is no clinical ulcer incidence data, no ulcer healing data, and no randomised long-term outcome data. There is also almost no human evidence on how capsaicin interacts with H. pylori infection, which is the pathway that actually matters. No pooled human effect size exists, and stating one here would be fabrication. Satyanarayana, Critical Reviews in Food Science and Nutrition 2006;46(4):275–328, a narrative review drawing predominantly on animal data. Cui bono: this is the highest-risk overclaim in the entry. Chilli producers, capsaicin supplement sellers and ancestral-food content all benefit enormously from the leap from "not harmful" to "protective", because it converts a null result into a reason to buy. Against: bland-diet and acid-suppression interests would benefit from it staying buried, but honestly the observed failure mode here is over-selling, not suppression. The person most protected by holding this claim down is the reader with an actual infection who might otherwise delay eradication therapy.

Sub-area C: The mortality epidemiology

5. In a very large Chinese cohort, more frequent spicy food consumption was associated with lower total mortality. [Moderate] The China Kadoorie Biobank followed 487,375 adults aged 30 to 79 — 199,293 men and 288,082 women — enrolled between 2004 and 2008 across ten geographically diverse areas, excluding those with cancer, heart disease or stroke at baseline. Over 3,500,004 person-years and a median 7.2 years of follow-up there were 20,224 deaths. Adjusted hazard ratios against eating spicy food less than once a week were 0.90 (95% CI 0.84–0.96) at one to two days a week, 0.86 (0.80–0.92) at three to five days, and 0.86 (0.82–0.90) at six to seven days. Cause-specific associations at the highest frequency: cancer 0.92 (0.85–0.99), ischaemic heart disease 0.78 (0.67–0.89), respiratory disease 0.71 (0.62–0.81). Fresh chilli showed stronger associations than non-fresh, and the inverse association was stronger among non-drinkers than regular drinkers (P=0.033 for interaction). The confounds, several conceded by the authors themselves: reverse causation, since people with chronic illness may already have stopped eating spicy food and the baseline-disease exclusion only partly addresses this; residual confounding by unmeasured biological and social factors, explicitly named; no adjustment for total energy intake because the dietary data were not detailed enough, so spicy food may be proxying for an entire cuisine, a region, fresh vegetable intake, or cooking at home rather than eating out; self-reported frequency with incomplete questionnaire validation and no dose or capsaicin quantity; and correlation with smoking, alcohol and socioeconomic status. Note the shape as well as the size, and note it carefully. The adjusted hazard ratio drops to 0.90 at one to two days a week and then sits at 0.86 for both higher categories — it plateaus rather than grading, so above about two days a week more is not better, which is an "any versus almost none" pattern rather than a dose-response. The crude mortality rates in the paper are 6.1, 4.4, 4.3 and 5.8 deaths per thousand person-years across the four categories, which is non-monotonic and rises back toward the reference at the highest intake — but those rates are unadjusted for age and sex, which is precisely why they differ from the modelled hazard ratios, and they should not be pressed into service as a dose curve in either direction. The plateau in the adjusted figures is the load-bearing observation; the crude rates are not. Lv, Qi, Yu and colleagues for the China Kadoorie Biobank collaborative group, BMJ 2015;351:h3942. Cui bono: this was a global press event in August 2015 and remains the load-bearing citation for every chilli-longevity headline, hot sauce brand and capsaicin supplement. The relative framing, a fourteen percent lower hazard, is what gets quoted; the plateau and the authors' own limitations section never are. An accompanying editorial at the time asked whether chilli is actually good for you rather than endorsing the causal reading. In the other direction there is no commercial interest in suppressing this at all, which matters: the reason to hold it down is epistemic rather than financial. A fourteen percent relative hazard difference in an unrandomised dietary exposure with no energy adjustment is precisely the effect size that nutritional epidemiology has repeatedly failed to reproduce in trials.

6. A United States cohort found a similar direction. [Emerging] Chopan and Littenberg analysed 16,179 adults in the third National Health and Nutrition Examination Survey with a median follow-up of 18.9 years, 4,946 deaths and 273,877 person-years. Crude total mortality was 21.6 percent in chilli consumers against 33.6 percent in non-consumers, and the adjusted hazard ratio was 0.87 (95% CI 0.77–0.97; P=0.01), around thirteen percent lower. Two fidelity points. The crude relative risk of 0.64 is the figure that circulated in media coverage and is not the adjusted result; using it would be a citation-fidelity failure. And the authors reported the adjusted association as significant — the observation that the upper confidence bound of 0.97 sits close to the null is this entry's deflationary reading, not a caveat the authors offered, and it should not be attributed to them. The confounds are severe on their own terms: chilli exposure came from a single baseline food-frequency item ascertained around 1988 to 1994 and then carried across nearly two decades of follow-up with no update, so a participant's diet in 2005 is simply unmeasured. Consumers differed systematically at baseline, being younger, more often male, more often smokers, lower income, and higher in both vegetable and meat intake, so the statistical adjustment is doing enormous work. Chopan and Littenberg, PLoS ONE 2017;12(1):e0169876. Cui bono: "now American data confirms it" is the phrase that turns one confounded cohort into an apparent consensus. Two observational studies pointing the same way in populations with radically different cuisines is genuinely mildly reassuring, but it is sold as replication when the shared weakness, unmeasured dietary and lifestyle confounding, is identical in both. Agreement between them is exactly what you would expect if the effect were entirely confounded. There is no commercial suppression on the other side; naming the weakness simply stops a reader concluding that two cohorts equals proof.

Sub-area D: Metabolic effects

7. Capsaicinoids increase energy expenditure by roughly fifty calories a day. [Moderate] A systematic review screened ninety trials, included twenty with 563 participants, and arrived at that figure, stating that it "would produce clinically significant levels of weight loss in 1–2 years." That projection is arithmetic, not an observed outcome; no trial in the review demonstrated weight loss over one to two years. The same review also reported that regular consumption "significantly reduced abdominal adipose tissue levels" — worth naming because it cuts against a purely deflationary reading, and worth immediately qualifying, because it pools short heterogeneous trials on a body-composition surrogate rather than a maintained weight outcome. On the authors' own posture, be accurate rather than convenient. The much-quoted "not a magic bullet for weight loss" is a concessive clause; the full sentence reads "While capsaicinoids are not a magic bullet for weight loss, the evidence is that they could play a beneficial role, as part of a weight management program." These authors did not decline the weight-management framing, they endorsed a modest version of it. The deflation in this entry is the entry's own judgement, argued from the effect size: fifty calories a day is roughly one biscuit and sits well inside ordinary intake variation, and habituation in regular consumers is well documented. Whiting, Derbyshire and Tiwari, Appetite 2012;59(2):341–348. Cui bono: this is the commercial core of the whole topic. Capsaicin and capsinoid extracts are sold as thermogenic fat burners and the fifty-calorie figure is the number on the label, alongside a one-to-two-year weight loss that was extrapolated rather than observed — and, importantly, extrapolated by the review itself, which is why "the supplement industry distorted the paper" is not an available defence here. Supplement sellers benefit directly and substantially, and some of this literature sits close to capsinoid ingredient manufacturers, which is worth checking on any individual trial before leaning on it. In the other direction, pharmaceutical weight-management interests benefit from small food-based effects being dismissed outright, and in the GLP-1 era a fifty-calorie food effect is trivially outcompeted. In this instance the dismissal happens to be largely correct on the merits.

8. Capsaicinoids taken before a meal reduce how much is eaten at that meal by about seventy-four calories. [Moderate] A meta-analysis identified seventy-four clinical trials, included ten, and pooled eight with analysable data from 191 participants across nineteen effect sizes, finding a reduction in ad libitum energy intake of 309.9 kilojoules, or 74.0 calories, during the meal following a pre-load (p<0.001), with a stated minimum effective dose of two milligrams of capsaicinoids. The authors explicitly warned that the result "should be viewed with some caution as heterogeneity was high," reporting I² of 75.7 percent, and called for long-term randomised trials — while nonetheless concluding that "there may be potential for capsaicinoids to be used as long-term, natural weight-loss aids," which is a further reach than their own data supports and should be read as the authors' lean rather than as a finding. The critical limit is that this is a single-meal acute effect measured immediately after a pre-load; compensation at later meals was not tracked over time, so it does not establish that daily intake falls. These two numbers must not be welded together into a combined daily deficit — they come from different reviews with different trial sets and different endpoints. Whiting, Derbyshire and Tiwari, Appetite 2014;73:183–188. Cui bono: identical to the previous claim. Appetite suppression is the second half of the fat-burner pitch, and the acute single-meal design is the part that never makes it onto the label. Against: nobody has an interest in suppressing a seventy-four-calorie finding; it is simply too small to matter commercially in the other direction.

Sub-area E: The genuine cautions

9. Spicy food triggers reflux symptoms in some people, but blanket restriction is not supported. [Moderate] An evidence-based review of roughly a hundred studies of lifestyle modification in gastro-oesophageal reflux disease found no evidence that dietary interventions, including avoiding spicy foods, coffee, chocolate, citrus or mint, improved objective measures or symptoms; only weight loss and elevation of the head of the bed were supported. Mechanistically this is consistent: laboratory work shows spicy food has little to no effect on lower oesophageal sphincter pressure, so chilli is not producing more reflux. What it does is activate mucosal TRPV1 nociceptors and produce a heartburn-like sensation directly, and in an already-inflamed oesophagus that mucosa is sensitised. The honest model is that chilli does not worsen the disease but can worsen the sensation, in some people and not others. Note the citation boundary: this review covers reflux disease only and must not be stretched to cover irritable bowel syndrome, gastritis or ulcer management. Kaltenbach, Crockett and Gerson, Archives of Internal Medicine 2006;166(9):965–971. Cui bono: the blanket "avoid spicy food" instruction is free for a clinician to issue, feels responsible, and shifts responsibility to the patient. It persists because nobody is penalised for giving it, not because it works, and diet-book and elimination-protocol authors benefit from long trigger lists. In the other direction, chilli producers and "the food rules were wrong" content benefit from the finding that dietary restriction lacks support, and could over-read it into "spicy food is fine for reflux", which is wrong for the individuals whose symptoms genuinely track chilli. The honest middle serves the patient and nobody's product.

10. Chilli triggers symptoms in irritable bowel syndrome. [Emerging] Directionally supported and biologically coherent, but stated here generically because no specific trial was confirmed to primary source in the verification pass for this entry, and inventing a citation would be worse than the gap. What is established generally: capsaicin affects visceral sensory perception, chillies accelerate gut transit, and small crossover studies in irritable bowel syndrome report increased postprandial abdominal burning and pain after chilli, disproportionately in the diarrhoea-predominant subtype. There is a parallel literature reporting increased TRPV1-expressing sensory fibres in rectal biopsies from patients with the condition, correlating with abdominal pain, which would explain why an identical dose hurts more in that gut. Structural limitation worth naming for the whole field: you cannot blind a capsaicin dose that burns, which caps the achievable quality of every symptom trial in this topic. Cui bono: low-FODMAP and elimination-diet programmes benefit from every food being provisionally suspect, and chilli is an easy addition to a restriction list; restriction lists sell programmes. Against, chilli and "gut-healing spice" content benefit from the triggering being minimised. The person actually harmed by either error is the patient — over-restriction narrows a diet for no benefit, under-warning leaves someone in avoidable pain. Individual trial and reintroduction is the honest approach and it sells nothing.

11. Chilli worsens pain in acute anal fissure and after haemorrhoid surgery. [Emerging] Better evidenced than most people expect, because these are actual randomised trials rather than folklore, which is unusual for a "spicy food is bad for X" claim. But the two trials are not of equal design, and the difference matters.

The fissure trial is the good one. Gupta ran a prospective, randomised, placebo-controlled, double-blind crossover trial in patients with acute anal fissures, giving encapsulated chilli or placebo for one week alongside analgesics and a fibre supplement and then crossing over for a second week, scoring pain, anal burning and pruritus. Fifty subjects were recruited and forty-three completed. Daily mean pain score was 2.05 on chilli against 0.97 on placebo, and anal burning 1.85 against 0.71 — meaning chilli made it worse. Patient preference ran 81.3 percent for placebo against 13.9 percent for chilli. Encapsulating the chilli was a genuine attempt at blinding, which is more than most of this literature manages, though capsaicin's own sensory effects make true blinding difficult even in a capsule.

The post-haemorrhoidectomy trial is weaker than it is usually described. Gupta randomised sixty patients after haemorrhoidectomy for grade III or IV disease to antibiotics and analgesics alone, or to the same regimen plus three grams a day of chilli powder, and reported worse postoperative symptoms in the chilli arm. That is an active add-on against an unblinded control rather than a placebo-controlled comparison, and three grams of chilli powder eaten daily cannot realistically be blinded, whatever the paper is labelled. Do not describe this trial as placebo-controlled.

The narrow-research-base caveat is narrower than it first appears. Both trials are single-author papers by the same investigator, Pravin J. Gupta, working from one centre, and there is at least a third adjacent single-author trial by him on chilli after anal fissure surgery. This is one clinician's finding repeated across three related conditions, not independent confirmation, and it has not been replicated by another group. Fissure trial: Gupta PJ, Arquivos de Gastroenterologia 2008;45(2):124–127. Post-haemorrhoidectomy: Gupta PJ, World Journal of Surgery 2007;31(9). Cui bono: nobody sells anything by telling fissure patients to avoid chilli, and the absence of a commercial shadow slightly raises confidence in the finding — though single-investigator concentration is its own bias risk and partly offsets that. Chilli advocacy content skips these trials entirely because they are unglamorous. The main risk runs the other way — a real finding in one acute lesion being generalised into "chilli is bad for your bowel", which the evidence does not support.

12. Extreme-heat challenge products carry real risk, including a documented death. [Emerging] Harris Wolobah, aged fourteen, of Worcester, Massachusetts, died on 1 September 2023 after taking part in a chip challenge using Carolina Reaper and Naga Viper pepper extract. The state medical examiner gave the cause of death as cardiopulmonary arrest "in the setting of recent ingestion of food substance with high capsaicin concentration." The nuance is load-bearing and must travel with the case: the same autopsy documented an enlarged heart and a congenital anomaly described as myocardial bridging of the left anterior descending coronary artery. So this is not evidence that a concentrated capsaicin dose kills a healthy adolescent. It is evidence that an extreme capsaicin challenge can be the proximate trigger of a fatal cardiac event in someone with an undiagnosed structural heart abnormality, which is precisely why stunt products marketed to teenagers are dangerous: nobody knows in advance who carries one. The product was withdrawn from shelves within days, and a wrongful-death suit was filed in Suffolk Superior Court on 11 July 2024. Evidence status: a single case, verified through multiple independent outlets reporting the medical examiner's findings rather than through a peer-reviewed case report read directly. Frame it as a case, not as a hazard rate. There is a broader case-report literature on extreme exposures, including coronary vasospasm and reversible cerebral vasoconstriction after superhot peppers, which was not verified here and is therefore not cited. Cui bono: the clearest in the entire entry. The challenge-product industry and the platforms that monetise the videos benefited from every day the product stayed on shelves; the product's commercial logic was virality and the risk was externalised onto teenagers. In the other direction, anyone wanting to revive "spicy food is dangerous" can now cite a real death to relitigate a myth that is otherwise dead, which is exactly why the entry must state plainly that this involved concentrated pepper extract at heat levels no cuisine reaches, in a child with an undiagnosed heart defect, and has no bearing on whether ordinary spicy food is safe.

Mechanism

The receptor, and why burning is not burning. Capsaicin binds TRPV1, an ion channel on sensory nerve endings whose ordinary job is to report noxious heat and acidic conditions. Activating it produces the identical signal your nervous system would generate if the tissue were genuinely being heated. This is the single most important mechanistic fact in the entry, because it explains the myth: the sensation of burning is manufactured at the receptor and transmitted to the brain without any tissue actually being damaged. Chilli is a false alarm delivered directly to the alarm wire. Everything downstream — the sweating, the flushing, the pain, the eventual pleasant afterglow — follows from a nervous system responding correctly to a signal that happens to be untrue.

Why the ulcer story was plausible and still wrong. A person eats chilli, feels burning in the stomach, and infers erosion. The inference is reasonable and the physiology does not support it. Where an erosion already exists, the pain fibres exposed by that lesion respond more strongly, so the person with an ulcer really does hurt more after chilli than the person without one. That is a lesion reporting its presence, not a lesion being created. The causal agents are an organism that colonises the gastric mucosa and a class of drugs that suppresses the prostaglandins maintaining the mucosal defence layer.

How the proposed gastroprotection would work, if it works. Capsaicin-sensitive afferent neurons, when stimulated, release calcitonin gene-related peptide and related neuropeptides locally, and these increase gastric mucosal blood flow. Increased blood flow supports mucosal defence and repair. Reported additional effects include inhibition of acid secretion and stimulation of alkali and mucus secretion. This mechanism is well characterised in rodents and only sketchily demonstrated in humans, and the entry treats it as a hypothesis rather than a finding.

Why the thermogenic effect is real and small. TRPV1 activation drives sympathetic outflow and increases thermogenesis, including in brown adipose tissue. This is measurable in a metabolic chamber and it is genuinely happening. It is also on the order of fifty calories a day, which is a real number attached to an unimportant magnitude. The organism defends energy balance actively; a fifty-calorie perturbation is well within what appetite regulation absorbs without noticing.

Why habituation matters more than people expect. Repeated capsaicin exposure desensitises TRPV1 responses. This is the basis of topical capsaicin as an analgesic and it is why regular chilli eaters tolerate doses that would incapacitate a novice. It also undercuts the metabolic pitch structurally: the population being advised to eat chilli for thermogenesis is largely the population whose receptors have already adapted, and the acute-dosing trials that produced the effect sizes were mostly not run in habituated consumers.

Why the ecology explains nothing about you. Capsaicin appears to exist because it deters seed-destroying mammals while leaving seed-dispersing birds unaffected, and the receptor-level basis for that asymmetry is a well-reported line of work, though not one this entry verified to primary source. It is a beautiful piece of biology and it is a statement about Capsicum reproductive strategy. It does not imply that capsaicin is safe for humans, harmful to humans, or designed with humans in mind. Humans are, in this system, the mammal that decided it liked being deterred.

Risks And Contraindications

Acute anal fissure and the post-haemorrhoidectomy period. The best-designed symptom evidence in the topic says chilli makes this worse, with the caveat that it rests on one investigator's trials and has not been independently replicated. Avoid during the acute phase.

Irritable bowel syndrome, especially diarrhoea-predominant. A likely individual trigger, supported by small studies and by a plausible receptor-density mechanism. Test individually rather than assuming.

Gastro-oesophageal reflux disease. Not a disease-worsening agent as far as the evidence shows, but a genuine symptom trigger for a subset. Individualised avoidance only; blanket restriction lacks support and is deferred to the reflux entry.

Active gastritis or existing ulceration. Chilli will hurt more, because exposed nociceptors respond to it. This is a comfort matter, not evidence that chilli is causing the lesion, and it must not displace investigation of infection and drug causes.

Concentrated extract products and heat challenges. The only exposure in this entry with a documented death attached. The risk concentrates in people with undiagnosed cardiac abnormalities, which by definition cannot be screened for in advance by the person taking the challenge. Reported serious events in the wider case literature include coronary vasospasm, reversible cerebral vasoconstriction and oesophageal injury from violent vomiting.

Children. The fatal case was a fourteen-year-old. Ordinary culinary chilli is not a paediatric hazard; extract-based challenge products marketed through social platforms specifically are.

Topical and ocular contact. Capsaicin on mucous membranes and eyes causes severe pain, and transferring it from hands after handling chillies is the common route. Milk or a fat-based wash removes it better than water, which spreads it.

Anticoagulant interaction, flagged as uncertain. Capsaicin has been discussed as a possible interactant with warfarin and antiplatelet agents. The entry does not assert this, because it was not verified in this pass. Anyone on anticoagulation who is considering high-dose capsaicin supplements, as distinct from food, should raise it with their prescriber rather than relying on this entry.

What is not a contraindication: having had an ulcer in the past and now being treated; general "sensitive stomach" self-description without an identified condition; or a family history of ulcers. None of these are reasons to avoid ordinary spicy food.

Controversy

The nature of the disagreement. Almost nobody argues about the underlying data any more. The dispute is entirely about how much weight the data can carry, and it is unusually symmetrical: one camp inherits a dead medical consensus and treats chilli as an irritant to be minimised, the other camp inherits two observational cohorts and two small meta-analyses and treats chilli as a functional food. Both are extrapolating past what their evidence supports, in opposite directions, from the same undisputed facts.

Position A: spicy food is a meaningful health-positive intervention.

Where it has the best evidence. The mortality associations are not nothing. Nearly half a million people followed for a median of seven years, with a consistent inverse association across cancer, ischaemic heart disease and respiratory mortality, and a smaller American cohort with a completely different cuisine pointing the same direction, is a real signal that deserves an explanation. The thermogenic and appetite effects are genuine, measured under controlled conditions, and mechanistically coherent through TRPV1-driven sympathetic activation. The review authors themselves concluded that capsaicinoids "could play a beneficial role, as part of a weight management program," so this position is not merely a distortion of the literature by people who did not read it. The gastroprotective mechanism has a plausible physiological pathway. And the position has the rhetorical advantage of being the one that corrected a genuine historical error.

Where it overreaches. The mortality cohorts could not adjust for total energy intake, measured exposure once by self-reported frequency with no dose, and could not fully exclude reverse causation, all of which their own authors state. The adjusted hazard ratios plateau above roughly two days a week — 0.90, then 0.86, then 0.86 — which is not the shape you would expect from a dose-dependent physiological effect, and this is the internal contradiction the position rarely addresses. If the benefit ran through the thermogenic and appetite pathway, more should be better, and in the data more is not better. The metabolic numbers are then routinely mishandled: the one-to-two-year weight loss is an extrapolation nobody observed, the seventy-four-calorie intake reduction is a single acute meal, and the two figures are frequently added together by people who have not read either paper. The gastroprotection claim is predominantly rodent and gets presented as human.

Position B: spicy food is an irritant that sensitive people should avoid.

Where it has the best evidence. This position is right about the specifics and right more often than the "chilli is harmless" crowd concedes. The anal fissure trial is randomised, placebo-controlled and double-blind with the chilli encapsulated, which is a higher evidentiary standard than anything the pro-chilli position has for its health claims, and the post-haemorrhoidectomy trial is randomised and points the same way even though its control arm was not placebo-controlled. Symptom triggering in irritable bowel syndrome is biologically well grounded, with a receptor-density finding that explains it. A person with an inflamed oesophagus genuinely does experience more pain after chilli. And a child is dead from a capsaicin product.

Where it overreaches. It generalises acute-lesion findings into universal dietary rules. The evidence that chilli hurts an existing fissure says nothing about whether it harms an intact bowel. Blanket spicy-food restriction in reflux was examined systematically and did not survive. The ulcer claim, which is the position's historical anchor, is simply false and has been for forty years. And the fatal challenge case is routinely stripped of the two facts that make it interpretable: pepper extract at concentrations no food reaches, and a documented congenital cardiac anomaly in the victim.

The funding and bias dimension — cui bono, both ways.

On the pro side the money is straightforward and substantial. Capsaicin and capsinoid extracts are sold as thermogenic supplements, and the fifty-calorie figure is a label claim. Hot sauce is a growth category with an interest in health framing. Some of the capsinoid trial literature sits close to ingredient manufacturers, which is worth checking before leaning on any individual trial. It is also worth naming a subtler point: the review authors themselves projected one to two years of clinically significant weight loss, so the most commercially useful sentence in this literature was written by academics, not by marketers. The mortality cohort is a different case — it is a large academic biobank study whose authors were genuinely cautious in print — but its abstract is the most commercially exploited sentence in the topic. Content creators monetise "superfood" framings, and half a million participants sounds like certainty even when it is statistical power aimed at a badly measured exposure.

On the anti side the money is older and mostly historical, but it was enormous. The pre-1983 ulcer economy sold indefinite acid suppression and dietary management for a condition that turned out to be curable with a fortnight of antibiotics, and Marshall's own account is that resistance to the infectious theory was partly a defence of that market. Today the analogous interests are smaller: elimination-diet and low-FODMAP programmes benefit from long lists of suspect foods, because restriction is what they sell. There is also a non-commercial bias worth naming, since it drives more behaviour than the commercial one: telling a patient to avoid spicy food costs a clinician nothing, sounds responsible, and transfers responsibility to the patient. No one is ever audited for issuing it.

And there is one near-clean asymmetry. The anal fissure and haemorrhoidectomy findings have no commercial constituency in either direction — nobody profits from that advice — which modestly raises confidence in them relative to everything else in the topic. It is only near-clean because they come from a single investigator, and single-source evidence carries its own risk that no funding analysis will detect.

Realised Position: The ulcer myth is dead and should be stated as dead, at Foundational strength, without hedging. Capsaicin produces sensation without producing lesion, and the causal agents in peptic ulcer disease are an infection and a drug class. Everything positive beyond that is weaker than it sounds: the mortality association is real, is Moderate at best, plateaus rather than grading with intake, and does not license the word "extends." The metabolic effects are real and are small enough to be irrelevant to any actual weight outcome — and note that this is our judgement from the effect sizes, not a caution we can borrow from the primary authors, who leaned mildly the other way. The gastroprotective claim stays at Emerging and stays rodent-flagged, because the failure mode of overstating it is a person delaying treatment for a curable infection. The cautions are real but narrow and individual, they are about specific conditions rather than about chilli, the one with the strongest trial design is also the most temporary, and it rests on one investigator. Concentrated extract challenges are not food and are not covered by any of the above. The net: harmless to possibly mildly beneficial for most people, a genuine and individually identifiable trigger for a minority, dangerous only at stunt-product extremes. That position has no commercial constituency at all, which is a reasonable indicator that it is the one worth holding.

Cross-Pillar Connections

• gerd_diagnostic_lifestyle — owns the diagnosis and management of gastro-oesophageal reflux disease in full, including the interventions that actually have evidence behind them and the diagnostic pathway. This entry defers all reflux management there and retains only the narrow finding that blanket spicy-food restriction lacks support while individual symptom triggering is real.
• hemorrhoids_evidence_and_management — owns the assessment, treatment and post-surgical management of haemorrhoids and related anal conditions. This entry defers all of that and retains only the specific randomised trial finding that chilli worsens symptoms in acute anal fissure and after haemorrhoidectomy, which is a dietary caution rather than a treatment.
• plant_defence_compounds_and_xenohormesis — owns the general framework for why plants synthesise defensive chemicals, what that means for the humans eating them, and where the xenohormesis argument is and is not supported. This entry defers the whole framing question there and retains only capsaicin's specific ecology, flagged as a bird-and-rodent finding with no human implication.
• hormesis_and_adaptive_stress — owns the general principle that mild stressors can produce adaptive benefit, along with the conditions under which that principle holds and the many places it is invoked without support. This entry defers the principle and notes only that TRPV1 pharmacology can be narrated as hormetic without that narration constituting evidence.
• antinutrients_evidence_and_context — owns the parallel question of whether plant compounds commonly labelled harmful actually cause harm at dietary intakes, and the pattern of a real laboratory effect being generalised into a dietary rule. This entry defers that broader analysis and stands as a specific instance of the same pattern running in both directions at once.
• cruciferous_vegetables_and_goitrogens — owns the closely analogous case where a genuine biochemical effect became a population-wide avoidance rule that the evidence does not support. This entry defers the thyroid-specific material entirely and shares only the structural lesson about individual susceptibility versus blanket restriction.
• whole_food_emphasis — owns the general case for eating whole foods over isolated compounds. This entry defers that argument and supplies a concrete example of why it matters: dietary chilli in a mixed cuisine and a concentrated capsaicin extract have different risk profiles, and the fatal case in this entry involved the extract, not the food.

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

Toward a stronger positive position, we would need:

A randomised controlled trial of dietary capsaicin or chilli with a hard clinical endpoint — weight maintained at twelve months or longer, cardiovascular events, or all-cause mortality — showing benefit that survives an intention-to-treat analysis. Nothing in the current literature is randomised against an outcome anyone cares about.

Mortality cohort analyses that adjust for total energy intake and overall diet quality and retain the association. The single most damaging gap in the current epidemiology is that spicy food may simply be marking a cuisine, and no published analysis has removed that possibility.

A dose-response relationship that actually appears. The current adjusted hazard ratios plateau above roughly two days a week. If a well-measured cohort with quantified capsaicin exposure, rather than self-reported frequency, showed a graded relationship, that would substantially strengthen the causal reading.

Human gastroprotection data with clinical endpoints — ulcer incidence or healing rates in adequately powered randomised trials, ideally including people with H. pylori infection. That would move the gastroprotection claim from Emerging to Moderate. Rodent lesion models would not.

Toward a stronger negative position, we would need:

Prospective evidence of mucosal damage from ordinary culinary chilli intake in people with healthy gastrointestinal tracts, using endoscopic or histological endpoints rather than symptom scores. This has been looked for and not found, so its absence is meaningful, but a well-designed positive study would change the entry substantially.

Population-level evidence that habitual chilli consumption raises the incidence of any specific gastrointestinal pathology after adjustment. The gastric cancer literature has been mixed and confounded by H. pylori prevalence and by preservation methods in high-consumption regions; a clean analysis showing harm would matter.

A pattern of serious adverse events at ordinary dietary exposures rather than at extract concentrations. The current serious-harm signal lives entirely in the stunt-product tail.

Larger, multi-centre replication of the fissure and haemorrhoidectomy findings by an investigator other than the one who produced them, which would strengthen those specific cautions rather than the general negative position.

What would NOT move us:

Another observational cohort finding the same inverse mortality association. Adding a third confounded cohort to two confounded cohorts does not produce causal evidence; the shared weakness is unmeasured dietary and lifestyle confounding, and agreement between studies with identical blind spots is exactly what confounding predicts.

More rodent gastroprotection work. The animal case is already made and it is already not sufficient. Another mouse gastric-lesion model changes nothing about human ulcer outcomes.

Larger meta-analyses of acute thermogenesis or single-meal intake. The effect sizes are not in serious dispute; their triviality is the point. A more precise estimate of fifty calories a day is still fifty calories a day.

Additional individual case reports from extreme-heat challenges. The hazard of concentrated extract stunts is established and already stated. More cases would confirm a position the entry already holds and would still not bear on ordinary dietary chilli.

Mechanistic plausibility arguments in either direction. TRPV1 pharmacology can be told as a story about beneficial hormetic stimulation or as a story about repeated nociceptor irritation, and both stories are internally coherent, which is precisely why neither counts as evidence.

Media coverage, cuisine-based reasoning about long-lived populations, or the observation that a billion people eat chilli daily without apparent harm. That last one is not nothing, and it is part of why the entry is relaxed about ordinary intake, but it is ecological reasoning and cannot distinguish "harmless" from "beneficial."

Industry bias note

Structural incentives the evidence base may reflect

The pro-capsaicin end. The supplement industry is the clearest interested party. Capsaicin and capsinoid extracts are sold as thermogenic fat burners, and the marketing runs directly on the fifty-calorie-per-day figure and the projected one-to-two-year weight loss. The uncomfortable detail, and the one most often got wrong in critiques of this industry, is that both of those numbers come from the academic review itself rather than from the marketing department — the review projected the one-to-two-year weight loss and concluded that capsaicinoids "could play a beneficial role, as part of a weight management program." What the labels drop is not a warning the authors issued, it is the surrounding evidence about effect size. The single-meal seventy-four-calorie intake reduction is the second half of the pitch, presented as if it were a daily deficit rather than an acute measurement taken immediately after a pre-load. Part of the capsinoid trial literature sits close to ingredient manufacturers, so funding disclosures deserve individual inspection on any trial being leaned on. Beyond supplements, the hot sauce and chilli category is commercially motivated to adopt health framing, and the 2015 mortality cohort gave it the perfect asset: a study whose sample size sounds like proof. Health content creators monetise the same framing at scale, and the directed-deterrence story from plant ecology gets pressed into service as an implied safety argument for humans, which it is not.

The anti-capsaicin end. The historical bias here was larger than anything on the pro side, and it is instructive precisely because it is now visible. Before 1983, ulcer management was a durable chronic-treatment market built on acid suppression and dietary restriction, and the infectious theory threatened it. That the discoverer of the causal organism has said publicly that resistance was partly market-defensive should be read as a permanent caution about how long a wrong consensus can be sustained when a business depends on it. The contemporary analogues are smaller but structurally similar: elimination-diet programmes, low-FODMAP protocols and diet books benefit from expansive lists of suspect foods, because the restriction is the product. And there is a large non-commercial bias that probably drives more clinical behaviour than any of the above — a blanket "avoid spicy food" instruction is free to issue, sounds responsible, transfers responsibility to the patient, and carries no professional risk if it is useless.

The clean signal. Three findings in this entry have little or no commercial constituency on either side, and they are correspondingly the ones to trust most.

The first is the ulcer refutation itself, which now has no financial defender in either direction and is simply established.

The second is the anal fissure and post-haemorrhoidectomy trial evidence. Nobody makes money telling fissure patients to skip chilli for a week, and nobody makes money suppressing that advice. The fissure trial in particular made an unusually honest design attempt — encapsulating the chilli to approach blinding — and the absence of any commercial shadow raises its relative credibility. The offsetting weakness is not financial but structural: both trials, and a third adjacent one, come from the same single investigator at one centre, and no other group has replicated them. Absence of a funding conflict is not the same as independence.

The third is the flat top of the mortality curve. Once someone is eating spicy food at all, the adjusted hazard ratio stops improving — 0.90, then 0.86, then 0.86 — and that plateau is a detail nobody has an interest in promoting, on either side. It was reported honestly in the primary paper and it undercuts the causal reading that the same paper's abstract is used to support. Note the discipline required here: the crude, unadjusted death rates in that paper are non-monotonic and are sometimes quoted as though they made this point more dramatically, but they are not adjusted for age or sex and cannot carry the argument. The adjusted plateau can. When a study's own modelled numbers argue against the way the study is marketed, those numbers are the signal.

One further structural observation: the honest middle position of this entry — mostly harmless, occasionally a trigger, dangerous only as a stunt — sells nothing to anyone. No product follows from it. In a topic this commercially contested, a position with no constituency is usually the one that survived the incentives rather than being shaped by them.

Capsaicin and Spicy Food: What It Actually Does